Quick Answer
ABBOTT LABORATORIES reported Operating Income of $8.05 billion for fiscal year 2025.
ABBOTT LABORATORIES Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $8.05B | +18.0% |
| 2024 | $6.83B | +5.4% |
| 2023 | $6.48B | -22.5% |
| 2022 | $8.36B | -0.7% |
| 2021 | $8.43B | +57.3% |
| 2020 | $5.36B | +18.2% |
| 2019 | $4.53B | +24.2% |
| 2018 | $3.65B | +133.4% |
| 2017 | $1.56B | -48.3% |
| 2016 | $3.03B | +5.5% |
| 2015 | $2.87B | +10.3% |
| 2014 | $2.60B | +21.8% |
| 2013 | $2.13B | +56.8% |
| 2012 | $1.36B | -16.5% |
| 2011 | $1.63B | -73.2% |
| 2010 | $6.09B | -2.4% |
| 2009 | $6.24B | +9.5% |
| 2008 | $5.69B | +24.4% |
| 2007 | $4.58B | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.06B | +10.7% | +0.2% |
| June 30, 2025 | $2.05B | +22.9% | +21.2% |
| March 31, 2025 | $1.69B | +22.2% | -8.9% |
| September 30, 2024 | $1.86B | +12.9% | +11.4% |
| June 30, 2024 | $1.67B | +8.2% | +20.4% |
| March 31, 2024 | $1.39B | -8.2% | -15.8% |
| September 30, 2023 | $1.65B | -6.9% | +6.8% |
| June 30, 2023 | $1.54B | -35.1% | +2.2% |
- ABBOTT LABORATORIES showed an increase of +18.0% in Operating Income compared to the prior fiscal year.
- Over the 2007–2025 period, ABBOTT LABORATORIES’s operating income has grown by 75.9% (from $4.58 billion to $8.05 billion).
- The most recent figure is from ABBOTT LABORATORIES’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: